Disclosed is the use of mazindol for preparing a medication intended for the preventive and/or curative treatment of attentiondeficit/hyperactivity disorder (ADHD) according to the DSM IV criteria in a patient in need of such treatment. Also disclosed is a pharmaceutical composition comprising a therapeutically effective amount of mazindol and a therapeutically effective amount of iron or one of its pharmaceutically acceptable salts and/or a psychostimulant which is a dopamine.
